Log In
Print
BCIQ
Print
Print this Print this
 

luspatercept (ACE-536)

  Manage Alerts
Collapse Summary General Information
Company Acceleron Pharma Inc.
DescriptionModified activin receptor type 2B (ACVR2B) fusion protein that inhibits several ligands in the transforming growth factor (TGF) beta superfamily
Molecular Target Activin receptor type 2B (ACVR2B)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$242.0M

$25.0M

$217.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today